Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
24 oct. 2022 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
10 oct. 2022 08h00 HE
|
Morphic Therapeutic
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor ...
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease
06 sept. 2022 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today...
First Wave BioPharma, Inc. Announces Reverse Stock Split
25 août 2022 12h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Metacrine Reports Second-Quarter 2022 Results
09 août 2022 16h05 HE
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...
First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio
27 avr. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
WisdomTree Launches Portfolio and Growth Solutions
18 avr. 2022 08h30 HE
|
WisdomTree Investments, Inc.
NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- WisdomTree Investments, Inc. (NASDAQ: WETF), an exchange-traded fund (“ETF”) and exchange-traded product (“ETP”) sponsor and asset manager, announced...
Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development
06 avr. 2022 08h00 HE
|
Morphic Therapeutic
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron Pelta promoted to Senior Vice President, Business and Corporate Development;...
Metacrine Reports Fourth-Quarter 2021 Results
30 mars 2022 16h05 HE
|
Metacrine, Inc.
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...
Metacrine Announces Executive Leadership Changes
24 févr. 2022 16h05 HE
|
Metacrine, Inc.
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...